NASDAQ:GRPH

Graphite Bio (GRPH) Stock Forecast, Price & News

$2.97

+0.05 (+1.71%)

(As of 06/2/2023 ET)

Compare

Today's Range: $2.87
▼
$2.97
50-Day Range: $2.41
▼
$3.38
52-Week Range: $1.59
▼
$4.48

Volume: 106,973 shs
Average Volume: 226,566 shs
Market Capitalization: $172.56 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.33

Graphite Bio MarketRank™ Forecast

Analyst Rating: Hold
1.89 Rating Score
Upside/Downside: 12.2% Upside
$3.33 Price Target
Short Interest: Healthy
2.77% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.05) to ($0.84) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars

Medical Sector

779th out of 983 stocks

Biological Products, Except Diagnostic Industry

128th out of 164 stocks

1.9

Analyst's Opinion

Consensus Rating
Graphite Bio has received a consensus rating of Hold. The company's average rating score is 1.89, and is based on no buy ratings, 8 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $3.33, Graphite Bio has a forecasted upside of 12.2% from its current price of $2.97.
Amount of Analyst Coverage
Graphite Bio has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.77% of the float of Graphite Bio has been sold short.
Short Interest Ratio / Days to Cover
Graphite Bio has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
Graphite Bio does not currently pay a dividend.
Dividend Growth
Graphite Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GRPH.

1.8

News and Social Media Coverage

News Sentiment
Graphite Bio has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Graphite Bio this week, compared to 1 article on an average week.
Search Interest
1 people have searched for GRPH on MarketBeat in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Graphite Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
38.45% of the stock of Graphite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
52.51% of the stock of Graphite Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Graphite Bio are expected to grow in the coming year, from ($1.05) to ($0.84) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Graphite Bio is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Graphite Bio is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Graphite Bio has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Graphite Bio (NASDAQ:GRPH) Stock

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Receive GRPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Graphite Bio and its competitors with MarketBeat's FREE daily newsletter.

GRPH Stock News Headlines

May 31, 2023 | americanbankingnews.com

Graphite Bio, Inc. (NASDAQ:GRPH) Receives Average Rating of "Reduce" from Brokerages

May 21, 2023 | americanbankingnews.com

Cantor Fitzgerald Analysts Reduce Earnings Estimates for Graphite Bio, Inc. (NASDAQ:GRPH)

June 2, 2023 | Legacy Research (Affiliate) (Ad)

“Amazon Loophole” could hand you $28,544 in “royalty” payouts

Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.

May 15, 2023 | markets.businessinsider.com

SVB Securities Sticks to Their Hold Rating for Graphite Bio (GRPH)

May 15, 2023 | finance.yahoo.com

Graphite Bio, Inc.'s (NASDAQ:GRPH) largest shareholders are private equity firms with 43% ownership, institutions own 22%

May 10, 2023 | finance.yahoo.com

Should You Buy Graphite Bio (GRPH) Ahead of Earnings?

May 4, 2023 | americanbankingnews.com

Analysts Set Graphite Bio, Inc. (NASDAQ:GRPH) Price Target at $3.33

April 21, 2023 | americanbankingnews.com

Reviewing Sangamo Therapeutics (NASDAQ:SGMO) & Graphite Bio (NASDAQ:GRPH)

June 2, 2023 | Behind the Markets (Ad)

U.S. Loses to China in Shocking WAR GAMES

=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>

April 9, 2023 | americanbankingnews.com

Graphite Bio, Inc. (NASDAQ:GRPH) Receives $3.33 Average PT from Analysts

April 1, 2023 | finanznachrichten.de

Northern Graphite Corporation: Northern Graphite Increases Size of Mousseau West Project

March 25, 2023 | finance.yahoo.com

We're Keeping An Eye On Graphite Bio's (NASDAQ:GRPH) Cash Burn Rate

March 24, 2023 | americanbankingnews.com

Royal Bank of Canada Trims Graphite Bio (NASDAQ:GRPH) Target Price to $3.00

March 23, 2023 | americanbankingnews.com

FY2023 EPS Estimates for Graphite Bio, Inc. (NASDAQ:GRPH) Lifted by Analyst

March 23, 2023 | americanbankingnews.com

Q1 2023 EPS Estimates for Graphite Bio, Inc. (NASDAQ:GRPH) Raised by SVB Leerink

March 22, 2023 | americanbankingnews.com

Graphite Bio (NASDAQ:GRPH) Issues Earnings Results

March 22, 2023 | americanbankingnews.com

Graphite Bio (NASDAQ:GRPH) Posts Earnings Results, Beats Estimates By $0.05 EPS

March 21, 2023 | markets.businessinsider.com

BTIG Sticks to Its Hold Rating for Graphite Bio (GRPH)

March 20, 2023 | finance.yahoo.com

Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results

February 24, 2023 | marketwatch.com

Graphite Bio to Reduce Workforce by 50%, Explores Strategic Alternatives

February 24, 2023 | benzinga.com

Graphite Bio shares are trading higher after the company announced a process to explore strategic alternatives.

February 23, 2023 | finance.yahoo.com

Sickle-cell gene therapy developer stops program, cuts half of staff

February 23, 2023 | msn.com

Graphite Bio adds 10%, most in eight months even as downgrades pile up

February 22, 2023 | finance.yahoo.com

Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring

January 25, 2023 | markets.businessinsider.com

Expert Ratings for Graphite Bio

January 10, 2023 | finance.yahoo.com

Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround

January 9, 2023 | msn.com

Looking Into Graphite Bio's Recent Short Interest

See More Headlines

GRPH Price History

30 days | 90 days | 365 days | Advanced Chart

GRPH Company Calendar

Last Earnings: 5/11/2023
Today: 6/02/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GRPH
CUSIP: N/A
CIK: 1815776
Web: www.graphitebio.com
Phone: 650-484-0886
Fax: N/A
Employees: 69
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.33
High Stock Price Forecast: $7.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +12.2%
Consensus Rating: Hold
Rating Score (0-4): 1.89
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.80)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-101,050,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -31.47%
Return on Assets: -29.25%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 18.85
Quick Ratio: 18.85

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.75 per share
Price / Book: 0.63

Miscellaneous

Outstanding Shares: 58,100,000
Free Float: 35,762,000
Market Cap: $172.56 million
Optionable: Not Optionable
Beta: 0.09

Key Executives

Dr. Joshua Lehrer-Graiwer FACC (Age 48)
M.D., Pres, CEO & Director
Comp: $724.58k

Dr. Matthew Porteus M.D. (Age 57)
Ph.D., Academic Founder & Director
Comp: $90.77k

Dr. Maria Grazia Roncarolo M.D. (Age 68)
Ph.D., Academic Founder & Chair of Scientific Advisory Board
Comp: $70k

Mr. Philip P. Gutry (Age 49)
Chief Bus. Officer
Comp: $541.33k

Dr. Daniel Dever Ph.D.
Co-Founder & Head of Discovery Research

Ms. Alethia Rene Young (Age 43)
Chief Financial Officer

Dr. Christine Garrett P.M.P. (Age 51)
Ph.D., Chief of Staff & Sr. VP of Operations

Mr. Jerry Cacia (Age 55)
Chief Technical Officer

Dr. Jane Grogan Ph.D. (Age 54)
Chief Scientific Officer

Stephanie Yao
VP of Communications & Investor Relations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

GRPH Stock - Frequently Asked Questions

Should I buy or sell Graphite Bio stock right now?: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Graphite Bio in the last twelve months. There are currently 1 sell rating and 8 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GRPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRPH, but not buy additional shares or sell existing shares.
View GRPH analyst ratings or view top-rated stocks.
What is Graphite Bio's stock price forecast for 2023?: 9 brokerages have issued twelve-month price targets for Graphite Bio's shares. Their GRPH share price forecasts range from $2.00 to $7.00. On average, they predict the company's share price to reach $3.33 in the next twelve months. This suggests a possible upside of 12.2% from the stock's current price.
View analysts price targets for GRPH or view top-rated stocks among Wall Street analysts.
How have GRPH shares performed in 2023?: Graphite Bio's stock was trading at $3.32 at the beginning of 2023. Since then, GRPH stock has decreased by 10.5% and is now trading at $2.97.
View the best growth stocks for 2023 here.
When is Graphite Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our GRPH earnings forecast.
How were Graphite Bio's earnings last quarter?: Graphite Bio, Inc. (NASDAQ:GRPH) released its earnings results on Thursday, May, 11th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.08.
When did Graphite Bio IPO?: (GRPH) raised $224 million in an IPO on Friday, June 25th 2021. The company issued 14,000,000 shares at a price of $15.00-$17.00 per share.

What is Graphite Bio's stock symbol?: Graphite Bio trades on the NASDAQ under the ticker symbol "GRPH."
Who are Graphite Bio's major shareholders?: Graphite Bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include EcoR1 Capital LLC (14.67%), K2 Principal Fund L.P. (1.67%), Prosight Management LP (1.51%), Board of Trustees of The Leland Stanford Junior University (1.21%), BlackRock Inc. (0.87%) and Federated Hermes Inc. (0.70%). Insiders that own company stock include Biocapital LP Samsara and Phil Gutry.
View institutional ownership trends.
How do I buy shares of Graphite Bio?: Shares of GRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Graphite Bio's stock price today?: One share of GRPH stock can currently be purchased for approximately $2.97.
How much money does Graphite Bio make?: Graphite Bio (NASDAQ:GRPH) has a market capitalization of $172.56 million. The company earns $-101,050,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis.
How can I contact Graphite Bio?: The official website for the company is www.graphitebio.com. The company can be reached via phone at 650-484-0886 or via email at ir@graphitebio.com.

This page (NASDAQ:GRPH) was last updated on 6/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial